USPTO serial 78668046
MTM LABORATORIES
Reviewed by CopyMark Law Group
Reg. 3290364Status 710
- Filing date
- Status date
- Registration date
- Sep 11, 2007
- Examiner
- BENJAMIN, SARA NICOLE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with MTM LABORATORIES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Heidelberg 69120, DE
Heidelberg 69120, DE
Heidelberg 69120, DE
HEIDELBERG, DE
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic preparations, reagents and chemical test kits for detection of cancerous conditions, neoplastic conditions, inflammatory conditions, infectious conditions, degenerative conditions, genetically aberrant or diseased conditions, proliferatively aberrant or diseased conditions, vascular disease conditions, premalignant conditions, malignant conditions, cancer and inborn errors for scientific or research use | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical preparations for the treatment and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases and for the treatment of premalignant and malignant cancerous conditions, cancer and inborn errors; veterinary preparations for the treatment and prevention of neoplastic, inflammatory, infectious, degenerative, genetic and proliferative and vascular diseases and for the treatment of premalignant and malignant cancerous conditions, cancer and inborn errors in livestock, cattle, pigs, horses, deer, elk, moose, sheep, dogs, cats, mice, rats, monkeys, apes and birds; medical diagnostic reagents and kits, comprising of medical diagnostic reagents and assays, for detection of cancer and neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases and for the detection of premalignant and malignant cancerous conditions, cancer and inborn errors; medical diagnostic preparations namely in-vitro and in-vivo diagnostic test kits, comprising of medical diagnostic reagents and assays, diagnostic liquid-immuno-assay kits, comprising of medical diagnostic reagents and assays, diagnostic solid-phase immuno-assay kits, comprising of medical diagnostic reagents and assays, diagnostic strip-tests, comprising of medical diagnostic reagents and assays, diagnostic dip-stick-tests, comprising of medical diagnostic reagents and assays, point of care tests, comprising of medical diagnostic reagents and assays, diagnostic lateral-flow assay kits, comprising of medical diagnostic reagents and assays, diagnostic flow-through assay kits, comprising of medical diagnostic reagents and assays, diagnostic immuno-chromatographic kits, comprising of medical diagnostic reagents and assays; diagnostic equipment namely medical diagnostic test strips for use in early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative or vascular diseases, cotton, wood, and plastic sticks, cotton swabs and tampons for use in sampling, storing, transporting, preparing, enriching, concentrating, testing, analyzing and evaluating of biological material and samples in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative or vascular diseases; therapeutic compounds and substances, namely, vaccines for prevention and treatment of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative or vascular diseases | SECTION 8 - CANCELLED | — |
| 009 | Diagnostic equipment, namely, plates having multi-well arrays that can be used in chemical analysis, biological analysis or patterning for scientific, laboratory or medical research use; diagnostic equipment, namely, chromatography columns and clothing for use in laboratories for use in sampling, storing, transporting, preparing, enriching, concentrating, testing, analyzing and evaluating of biological material and samples in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative or vascular diseases | SECTION 8 - CANCELLED | — |
| 010 | Point-of-care testing machines, namely, for immunochemistry testing, medical diagnostic liquid-immuno-assay machines, medical diagnostic solid-phase immuno assay machines, medical diagnostic ELISA testing machines, medical diagnostic immuno-chromatographic machines; diagnostic equipment, namely containers for medical samples, vessels, namely, containers specially designed for storing and transporting medical samples, test tubes, namely, for medical samples and medical diagnostic testing, brushes, namely, for sampling of medical samples from body cavities and epithelia, medical syringes, needles for medical use, spatulas, namely, for medical samples and medical diagnostic testing, all for use in sampling, storing, transporting, preparing, enriching, concentrating, testing, analyzing and evaluating of biological material and samples in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative or vascular diseases; diagnostic nucleic acid detection machines, diagnostic nucleic acid amplification machines, diagnostic immuno-histology machines and diagnostic immuno-cytology machines all used to analyze and/or provide diagnostic test results and used in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious and genetic diseases associated with cancer, proliferative diseases associated with neoplastics and dysplastic conditions or vascular diseases | SECTION 8 - CANCELLED | — |
| 042 | Scientific analysis in the fields of chemistry, biology and molecular biology, laboratory research in the field of molecular biology; laboratory research in the fields of pharmaceuticals, chemistry, medical diagnostics and food technology; pharmaceutical research services, chemical research services and medical diagnostic research services for clinical, therapeutic, prophylactic and medical diagnostic applications and procedures; research and development of pharmaceutical products and substances for others; providing information on the subject of scientific research in the field of biochemistry, disease related molecular markers and molecular diagnostics; chemical, biological, molecular biology and pharmacogenomic analysis services | SECTION 8 - CANCELLED | — |
| 044 | Medical diagnostic services and provision of medical diagnostic information in the field of detection of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn errors, detection of neoplastic, inflammatory, infectious, degenerative, genetic and proliferative and vascular diseases; veterinary diagnostic services and provision of veterinary diagnostic information in the field of detection of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn errors; detection of neoplastic, inflammatory, infectious, degenerative, genetic and proliferative and vascular diseases; premalignant and malignant cancerous conditions, cancer and inborn errors in livestock, cattle, pigs, horses, deer, elk, moose, sheep, dogs, cats, mice, rats, monkeys, apes and birds | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MTM Laboratories AG
- Other trademarks owned by MTM Laboratories AG
- Other trademarks owned by MTM Laboratories AG
- Other trademarks owned by ROCHE MTM LABORATORIES AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MTM LABORATORIES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 18, 2014 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Mar 24, 2014 | WOAG | WITHDRAWAL OF ATTORNEY GRANTED | — |
| Mar 24, 2014 | WOAR | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | — |
| Apr 20, 2012 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 20, 2012 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 18, 2012 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Sep 11, 2007 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 26, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 6, 2007 | NPUB | NOTICE OF PUBLICATION | — |
| Apr 23, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 18, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 17, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 17, 2007 | ALIE | ASSIGNED TO LIE | — |
| Apr 16, 2007 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 16, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 22, 2007 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 21, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 21, 2007 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 21, 2006 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 21, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 31, 2006 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 7, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 7, 2006 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 4, 2006 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 15, 2006 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 15, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 1, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 18, 2005 | NWAP | NEW APPLICATION ENTERED | — |